Co-administration of dexamethasone increases severity and accelerates onset day of neutropenia in bladder cancer patients on methotrexate, vinblastine, adriamycin and cisplatin chemotherapy: a retrospective cohort study.

Shingo Itai,Yukio Suga,Yusuke Hara,Kouji Izumi,Yuji Maeda,Yasuhide Kitagawa,Junko Ishizaki,Tsutomu Shimada,Atsushi Mizokami,Yoshimichi Sai

Co-administration of dexamethasone increases severity and accelerates onset day of neutropenia in bladder cancer patients on methotrexate, vinblastine, adriamycin and cisplatin chemotherapy: a retrospective cohort study.

2017

Shingo Itai
Yukio Suga
Yusuke Hara
Kouji Izumi
Yuji Maeda
Yasuhide Kitagawa
Junko Ishizaki
Tsutomu Shimada
Atsushi Mizokami
Yoshimichi Sai

Background Bladder cancer patients receiving methotrexate, vinblastine, adriamycin and cisplatin (MVAC) chemotherapy are co-administered with dexamethasone as an anti-emetic. We examined whether or not dexamethasone affects the severity and onset day of MVAC-induced severe neutropenia.

Keywords:

Dexamethasone
Neutropenia
Medicine
Cisplatin
Vinblastine
Retrospective cohort study
Oncology
Methotrexate
Bladder cancer
Internal medicine
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations